Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow‐up

@article{Porpiglia2015TemporaryIN,
  title={Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow‐up},
  author={Francesco Porpiglia and Cristian Fiori and Riccardo Bertolo and Diletta Garrou and Giovanni M. Cattaneo and Daniele Amparore},
  journal={BJU International},
  year={2015},
  volume={116}
}
To report the first clinical experience with a temporary implantable nitinol device (TIND; Medi‐Tate®) for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). 

Second‐generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow‐up

TLDR
To report the clinical experience with a second‐generation of temporary implantable nitinol device for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) after 1 year of follow-up.

3‐Year follow‐up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction

TLDR
3‐year follow-up results of the first implantations with a temporary implantable nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) are reported.

Meditate Temporary Implantable Nitinol Device

TLDR
TIND can be a viable minimally invasive surgical approach in the treatment of lower urinary tract symptoms correlated to benign prostate hyperplasia and best candidates are patients who are unfit for major surgeries, patients who is refractory to standard medical treatment and patients who would like to preserve ejaculation.

iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia

TLDR
While the formal position of iTIND in current guidelines is yet to be determined, 12-month data demonstrates that it can improve both objective and subjective outcome measures, which are sustained at short-term follow up.

Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study

TLDR
ITind treatment for BPO-related LUTS showed marked and durable reduction in symptoms and improvement of functional parameters and quality of life at 24 months of follow-up and it was found that median lobe may predict failure of treatment.

3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.

TLDR
Treatment of BPO-related LUTS with iTIND demonstrated a significant and durable reduction in symptoms and improvement of functional parameters and quality of life at 3 years of follow-up.

First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature

TLDR
Current evidences emphasize that the temporary implantable nitinol devices are promising alternatives to the standard minimally invasive surgical options for BPH-related LUTS, allowing spare ejaculation in sexually active patients.

Functional Results after First- and Second-Generation Temporary Implantable Nitinol Device (TIND) for BPH: A Narrative Review of the Literature

TLDR
Current clinical evidence suggests that temporary implantation of first- and second-generation temporary implantable nitinol devices are valid options for the minimally invasive surgical treatment of BPH-related LUTS.

Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction

TLDR
An update on currently available mechanical devices for the treatment of LUTS/BPO including the prostatic urethral lift (PUL), the temporary implantable nitinol device, and new intraprostatic implants is provided.

Follow-up of Temporary Implantable Nitinol Device (TIND) Implantation for the Treatment of BPH: a Systematic Review

TLDR
The extended follow-up of the first and only available cohort of patients who underwent TIND for LUTS related to BPH corroborated previous literature findings and showed the TIND implantation is safe, effective, and well tolerated.
...

References

SHOWING 1-10 OF 37 REFERENCES

Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

To assess the clinical effect of the ‘prostatic urethral lift’ (PUL) on lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) through a crossover design study.

Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations.

TLDR
The current state of medical therapy for men with LUTS is reviewed and its promises and its current limitations are highlighted.

Minimally invasive therapies for benign prostatic hyperplasia

TLDR
Minimally invasive therapies are particularly useful in those on anticoagulants, in whom anesthesia is contraindicated and younger men with an active sex life and will not be able to replace TURP until their long-term durability of symptom relief is known.

Is transurethral resection of the prostate still justified?

TLDR
The objective of this review is to determine the current TUVP 4 27–30 199 189 status of TURP with particular reference to less invasive Holmium Laser procedures and recent developments of transurethral VLAP.